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Introduction
H
epatitis C virus (HCV) infection is globally 
a major cause of liver-related morbidity and 
mortality  (1-3).  It  is  estimated  that  around  170-200 
million  individuals  are  living  with  chronic  HCV 
infection worldwide and are at risk for hepatocellular 
carcinoma and cirrhosis (4, 5). The goal of therapy is to 
achieve a sustained virological response (SVR),defined 
as an elimination of the virus that is sustained for at 
least 6 months after the end of treatment. Attaining 
SVR prevents the development of cirrhosis, liver failure 
and hepatocellular carcinoma (HCC), and improves 
the infected patients’ quality of life (6). Interferon (IFN) 
alpha, an immune-response modifying agent that has a 
direct antiviral effect and enhances immune response 
to viruses, is the backbone of treatment for chronic 
HCV infection. However, monotherapy with IFN at 
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Background and Aims: Two types of peginterferon, alpha-2a (PEG-IFN-α2a) and 2b (PEG-IFN-α2b), are approved for the 
treatment of hepatitis C infection. Several high-quality studies have compared the efficacy of these two types of interferon, 
but it seems that any of these trials had inadequate statistical power on their own to find even a tiny difference between 
these two medicines. We pooled the available data in the literature to find any small difference between these two 
medicines.
Methods: In a systematic review of the literature, randomized controlled trials comparing the use of PEG-α2a vs. 2b 
were assessed. The DerSimonian and Laird method was employed to run meta-analysis. The end points were virological 
responses. 
Results: In 7 randomized controlled trials, 3518 patients were randomized to receive PEG-IFN-α2a + ribavirin (n=1762) 
or PEG-IFN-α2b + ribavirin (n=1756). Early virological response (EVR), early treatment response (ETR), and sustained 
virological response (SVR) were greater for patients treated with PEG-IFN-α2a. Odds Ratios (ORs) were 1.38 (95% 
confidence interval [CI] 1.11-1.71), 1.67 (95% CI 1.24-2.24), and 1.38 (95% CI 1.02-1.88) respectively. In the subset 
of naïve patients with genotype 1/4 and 2, ORs of SVR were 1.38 (95% CI 1.02-1.88) and 4.06 (95% CI 1.67-9.86) 
respectively. PEG-IFN-α2a had significantly higher rate of neutropenia OR=1.50 (95% CI 1.25-1.79) but pooled OR for 
withdrawal rates was not significant [OR=0.78 (95% CI 0.47-1.29)]. 
Conclusions: PEG-IFN-α2a with similar safety is more effective than PEG-IFN-α2b. A longer duration of maximum serum 
concentration compared with PEG-IFN-α2b (168 vs. 48-72 h.) yields a greater SVR and higher neutropenia in PEG-IFN-α2a 
recipients.
Keywords: Peginterferon Alpha-2a, Peginterferon Alpha-2b, Pegasys, PegIntron, HCV, Meta-Analysis, Systematic ReviewHepatitis Monthly, Spring 2010; 10(2): 121-131
122 IFN-α2a vs. IFN-α2b for Treatment of Chronic Hepatitis C
3 million units 3 times weekly for 48 weeks produces 
low SVR rates of 20% (7-11). The addition of ribavirin, 
a synthetic guanosine analogue that takes direct action 
against RNA and DNA viruses, to the standard IFN 
alpha, for a 48-week regimen produces SVRs up to a 
suboptimal level of 40% in naïve patients (12-14). An 
important recent advance in the treatment of chronic 
HCV was the introduction of a long-acting IFN known 
as peginterferon (PEG-IFN), which, in combination 
with ribavirin, further increases overall SVR rates up 
to 52% in patients with type 1, and 80% in patients 
with type 2 or 3 of HCV infection (15-18). PEG-IFN 
alpha is the product of a process called pegylation. In 
this process the polyethylene glycol molecule is bonded 
to  standard  IFN  covalently. The  polyethylene  glycol 
(PEG) part of the compound increases the biological 
half-life of the IFN protein and its biological effects 
by slowing the rate of absorption from subcutaneous 
sites, and protects the IFN molecule from proteolytic 
breakdown. Two types of PEG-IFN alpha are available. 
Both are type I alpha IFN, but differ in the size and 
structure  of  the  IFN  and  the  polyethylene  glycol 
molecules, as well as in pharmacokinetic properties. 
The US Food and Drug Administration has approved 
a fixed-dosing regimen for PEG-IFN alpha-2a (PEG-
IFN-α2a) with a molecular weight of 40 kDa (180 µg 
once weekly) and a weight-based regimen (1.5 µg/kg 
once weekly) for PEG-IFN alpha-2b (PEG-IFN-α2b) 
with a molecular weight of 12 kDa. At present dual 
therapy of both PEG-IFNs and ribavirin is the standard 
antiviral regimen for chronic HCV infection; however, 
current guidelines make no recommendation for one 
variety of pegylated IFN (PEG- IFN) over the other, and 
it is unclear if there are clinically significant differences 
between dual therapy with PEG-IFN-α2a and with 2b. 
A previously published systematic review has focused 
on comparing dual therapy with either PEG-IFN-α2a 
or 2b versus dual therapy with standard IFN, and then 
indirectly compared these two types of PEG-IFN (19). 
Since  then  several  head-to-head  randomized  clinical 
trials  (RCTs),  which  have  directly  compared  dual 
therapy with these two types of PEG-IFN, have been 
published, but a systematic review and meta-analysis of 
these RCTs has not been conducted yet. The purpose 
of this meta-analysis is to compare the advantages and 
disadvantages of dual therapy with PEG-IFN-α2a, with 
dual therapy with PEG-IFN-α2b, based on the results 
of head-to- head randomized controlled trials.
Materials and Methods
Search methods for the identification of studies
We made an electronic search of Medline, Scopus, 
the Cochrane Central Register of Controlled Trials, and 
ISI with different possible keywords for peginterferon 
alpha-2a and 2b. We did not apply any temporal limits. 
The keywords we used were different combinations of 
“hepatitis C virus” or “HCV” with following terms: 
“peginterferon alpha-2a” and “peginterferon alpha-2b”. 
In  different  queries,  “pegylated  interferon”  replaced 
“peginterferon” and “alfa” replaced “alpha” to retrieve 
all relevant citations. In another query, the commercial 
brand names were used; “Pegasys” and “PegIntron”. 
Data collection and analysis
All  citations  were  imported  into  an  EndNote 
library, then titles and abstracts were screened by two 
separate investigators that were blind to each other’s 
study selection. Full texts of all selected reports were 
retrieved  and  assessed  according  to  our  predefined 
inclusion and exclusion criteria. Data from studies that 
met our criteria were extracted by two investigators 
separately and rechecked by a third one. The data for 
outcome of treatment were tabulated according to 
the treatment regimen (dual therapy with PEG-IFN-
α2a  and  ribavirin  or  PEG-IFN-α2b  and  ribavirin) 
in  excel  spreadsheets.  The  decision  to  include  or 
exclude a study, and predefined assumptions, were 
made and agreed to by all authors before running 
the meta-analysis. The data for the characteristics of 
the studies and patients were abstracted by standard 
questionnaires including first author name, journal 
name,  methodology  of  randomization,  allocation 
concealment,  blindness  to  treatment,  publication 
year, and sample size in each treatment arm; as well 
as  viral  loads,  liver  histologies  and  frequencies  of 
genotypes, SVR (undetectable HCV-RNA 6 months 
after untreated follow-up), ETR (undetectable HCV-
RNA  immediately  on  treatment  cessation),  rapid 
virological response (RVR) (undetectable or >2Log 
reduction of serum HCV-RNA level after 4 weeks 
of therapy), EVR (undetectable or >2Log reduction 
HCV  RNA  after  12  weeks  of  therapy),  anemia, 
leukopenia, thrombocytopenia, depression and severe 
psychiatric disorders, flue-like syndrome and treatment 
discontinuation according to treatment arms.
Inclusion and exclusion criteria
Randomized  controlled  trials  of  adults  with 
chronic  HCV  infection  seronegative  for  human 
immunodeficiency virus (HIV) and hepatitis B virus 
(HBV) infection were included if study patients: 1) 
received PEG-IFN-α2a 180 µg per week plus ribavirin 
800-1400 mg in one treatment arm and PEG-IFN-
α2b 1.5 µg/kg per week plus ribavirin 800-1400 mg 
per day in another treatment arm, 2) were treated for 
at least 24 weeks if infected with HCV genotypes 2 or 
3, and for at least 48 weeks if infected with genotypes 
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required a detectable HCV RNA value and a duration 
of at least 6 months of infection. Articles in all languages 
that  met  the  criteria  were  included.  Inclusion  of 
patients with previous history of treatment, study dose 
modification, administration of growth factors, and 
antidepressants was allowed. Studies were excluded if 
study patients: 1) had decompensated liver disease, 2) 
had positive seromarkers for HIV or HBV infection 
3) were not all accounted for at the end of the study, 
4)  had  significant  co-morbidities,  and  5)  received 
lower than 1.5 µg/kg PEG-IFN-α2b or 180 µg PEG-
IFN-α2a. Quasi-experimental trials and observational 
studies were excluded as well.
End points of interest
The primary end point for comparison of efficacy 
was SVR, defined as undetectable HCV-RNA for the 
6 months after treatment cessation. The secondary end 
points of interest were: RVR defined as undetectable, 
or a reduction of more than 2log10 HCV-RNA after 4 
weeks of treatment; early virological response (EVR) 
defined as undetectable, or a reduction of more than 
2log10 HCV RNA at week 12 of treatment; and end 
of treatment response (ETR) defined as undetectable 
HCV RNA at the end of the course of treatment.
The primary end points for comparison of safety were 
withdrawals and dropouts. The secondary end points 
were dose modifications, adverse events including flu-
like syndrome and laboratory abnormalities defined 
as Hb < 10 g/dL, neutropenia (< 750 c/mm3) and 
thrombocytopenia (<50,000 c/mm3).
Assessment of methodological quality
Methodological quality, defined as confidence that 
the design and report will limit the chance of bias in 
intervention comparison, was evaluated, as previously 
reported  (20).  Allocation  sequence  generation, 
allocation concealment and blinding were extracted 
as measures of bias control. The allocation sequence 
generation was considered adequate if based on a 
table of random numbers or on computer-generated 
random numbers. The allocation concealment was 
considered  adequate  if  patients  were  randomized 
through a central independent unit or using serially 
numbered  opaque  sealed  envelopes  or  something 
similar. Blinding was described as adequate if the trial 
was described as double-blind, and both patients and 
investigators were unaware of the allocated treatment. 
To assess the risk of bias further, we also extracted the 
number and reasons for dropouts and withdrawals. 
Conflicts were resolved by consensus.
Source of support
This  meta-analysis  was  not  supported  by  any 
pharmaceutical company or government agency, or 
grants from other sources.
Data synthesis
All analyses were performed in Stata 10, (Stata Corp. 
College Station, TX, USA). Data on all randomized 
patients  were  included,  based  on  the  intention-to-
treat  principle,  irrespective  of  compliance  or  follow-
up.  To  manage  missing  data,  we  used  worst-case 
scenario analysis and, since we had a positive outcome 
(virological response), all missing data were counted as 
non-responders. Subgroup analyses on the SVR of naïve 
patients with genotype 1 or 4 and patients with genotypes 
2 and 3 were performed. The results are presented as an 
Odds ratio (OR) with a 95% confidence interval. Meta-
analysis was performed, using the random effects model 
of the DerSimonian and Laird method. The random 
effects model provides a more conservative estimate of 
significance. This model operates under the assumption 
that included studies are only a random sample of all 
studies that will be conducted, so that heterogeneity 
among individual studies will result in a wider CI of the 
summary estimate. Therefore, using the DerSimonian 
and Laird random effects model, the reported summary 
estimate was calculated as an average of the individual 
study results weighted by the inverse of their variance 
(21). The estimate of heterogeneity was taken from the 
Mantel-Haenszel model; under the null hypothesis of the 
test of heterogeneity, there is no difference in treatment 
effect among groups (this follows a א2 distribution with 
k-1 degree of freedom, where k is the number of studies 
contributing to the meta-analysis). Study results were 
considered heterogeneous if the resultant P-value was 
less than 0.1 (22). I2 was also used to provide a measure 
of the degree of inconsistency among the studies’ results. 
Its quantity describes the percentage of total variation 
across studies that is due to heterogeneity rather than 
chance. I2 lies between 0% and 100%. A value of 0% 
indicates no observed heterogeneity, and larger values 
show increasing heterogeneity (23).
Results
Results of the search
Our search strategy yielded 460 unique citations 
that included fourteen randomized clinical trials (24-37), 
four prospective (38-41) and five retrospective studies 
(42-46)  that  compared  PEG-IFN-α2a  plus  ribavirin 
with PEG-IFN-α2b plus ribavirin (Fig. 1). Among 
fourteen studies with randomized design, two studies 
were excluded because they were published as abstract 
proceedings (35, 36), one study was excluded because 
patients received 1 µg/kg of PEG-IFN-α2b (31), another 
study was excluded because patients received ribavirin 
after 4 weeks of monotherapy with PEG-IFN-α2a or Hepatitis Monthly, Spring 2010; 10(2): 121-131
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2b (30), another was excluded because patients did not 
undergo randomization according to type of PEG-
IFN, but according to standard treatment duration 
of either PEG-IFNs against individualized treatment 
duration based on viral kinetics (34), another one was 
excluded because it included patients with HIV/HCV 
co-infection (32). 
One thousand-sixteen subjects in one treatment 
arm of the study by McHutchison et al. were also 
excluded because patients received 1 µg/kg of PEG-
IFN-α2b.  One  duplicate  publication  of  the  same 
patients’ data was also excluded  (25). At the end, 7 
randomized clinical trials were included in a meta-
analysis (24-29, 33, 37) (Fig. 1). In two studies by Sporea 
and Di Bisceglie et al. only data of RVR or EVR were 
available for analysis (247 subjects in PEG-IFN-α2a 
arm and 249 in PEG-IFN-α2b arm).
Included studies 
Study characteristics are presented in table 1. of 
seven included studies, three were from Italy, two 
from the USA and one each were from Turkey and 
Romania.  All  studies  were  published  as  full  text  in 
peer-reviewed journals between 2006 and 2010. One 
study by Scotto et al. included only non-responders 
to previous combination therapy of standard IFN and 
Figure 1. Analysis of search results.
We reviewed titles and abstracts of 460 
unique citations that were retrieved
23 potential citations were selected
One duplicate publication of the 
same patients’ data was excluded
1016 subjects were discarded 
because they received 1µg/kg 
peginterferon alpha-2a
Seven studies comprising 3518 subjects with randomized design were included in our meta-analysis
Four non-randomized prospective studies were 
excluded
Five retrospective observational studies were 
excluded
One randomized study that included patients 
with HIV/HCV co-infection was excluded
Two randomized studies that were published as 
abstract proceeding were excluded
One randomized study was  excluded because 
ribavirin was started  after 4 weeks of 
monotherapy
One randomized study was excluded because 
patients received 1µg/kg of peginterferon
alpha-2b in one treatment arm
One randomized study was excluded because 
patients did not undergo randomization
according to the type of peginterferonHepatitis Monthly, Spring 2010; 10(2): 121-131
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α2a, the mean age in the subject cohort ranged from 
45 to 52 years of age; gender distribution ranged from 
27 to 61% male; hard-to-treat HCV types of 1/4 
ranged from 52 to 100%; viral load ranged from 570 
×103 to 3.1 × 106;, and the proportion of patients with 
cirrhosis ranged from 18 to 20%. In PEG-IFN-α2b 
recipients, the mean age ranged from 45 to 53 years 
of age; gender distribution ranged from 27 to 60% 
male; hard-to-treat HCV types of 1/4 ranged from 52 
to 100%; viral load ranged from 604 × 103 to 3.1 × 106 
and rate of cirrhosis ranged from 16 to 18%. All those 
studied included only naïve patients that did not have 
a history of previous anti-HCV treatment, except for 
two studies by Scotto and Sporea et al. that included 
193 subjects who were non-responders or relapsers to 
a previous combination therapy of standard IFN and 
ribavirin (81 patients were retreated with PEG-IFN-
α2a).
A comparison of the efficacy of PEG-IFN-α2a and 
PEG-IFN-α2b dual therapy with ribavirin in HCV- 
infected patients 
The probability of achieving SVR was higher in 
patients treated with PEG-IFN-α2a and ribavirin 
when compared with PEG-IFN-α2a and ribavirin, 
with an OR of 1.38 (95% CI 1.02-1.88; P=0.03) 
(Fig.  2).  Heterogeneity  was  significant  among  the 
included  studies  (P=0.05,  I2=55%).  The  odds 
of  achieving  early  (Fig.  3)  and  end  of  treatment 
virological response (Fig. 4) were also higher with 
PEG-IFN-α2a and ribavirin, with OR of 1.38 (95% 
CI 1.11-1.71; P=0.003, I2=29%) and 1.67 (95% CI 
1.25-2.24; P=0.001, I2=47%) respectively. There was 
no  discrepancy  between  rapid  virological  response 
rates  [OR=1.00  (95%  CI  0.77-1.30),  chi2(2)=3.4, 
I2=41%]. In the subset of naïve patients with genotype 
1/4 and 2 infection, OR of achieving SVR was also 
higher in those patients who received PEG-IFN-α2a 
plus ribavirin (Table 3).
A comparison of safety of PEG-IFN-α2a and PEG-
IFN-α2b  dual  therapy  with  ribavirin  in  HCV- 
infected patients
Withdrawal: All studies had sufficient information 
to enable comparison of the treatment discontinuation 
rates of those patients being treated with PEG-IFN-
α2a plus ribavirin, and those treated with PEG-IFN-
α2b plus ribavirin. Only patients who discontinued 
treatment  because  of  severe  adverse  events  or 
laboratory abnormalities were considered withdrawal 
data.  Patients  with  an  insufficient  viral  response, 
or those who did not return for other reasons were 
considered non-responders, and not included in the 
patient withdrawal data. Patients with both treatment 
regimens  had  similar  likelihood  of  treatment 
discontinuation  caused  by  laboratory  abnormalities 
or severe clinical adverse events. The OR was 0.75 
(95% CI 0.42-1.34) (Fig. 5). The heterogeneity was 
significant (P=0.02, I2=64%). Further analyses were 
completed  to  examine  patient  withdrawals  because 
of adverse effects and abnormal laboratory tests. The 
difference in withdrawal rates due to adverse events 
and laboratory abnormalities was not significant, with 
ORs of 0.72 [(95% CI 0.35-1.47), I2=63%] and 0.42 
[(95% CI 0.06-2.71), I2=50%] respectively.
Dose Modifications: Adequate data about dose 
modifications  were  available  in  all  studies  except 
Yanice et al.’s study. The discrepancy between dose 
modification  rates  of  PEG-IFN  or  ribavirin  was 
not significant between the two treatment regimens 
[OR=0.99(95%  CI  0.85-1.15).  No  heterogeneity 
was observed among the studies (P=0.6, I2=0). The 
difference between dose modification of these two 
types of PEG-IFN due to side effects or laboratory 
abnormalities  was  also  non-significant  with  low 
heterogeneity  [OR=  1.17  (95%  CI  0.94-1.46), 
I2=0%]
Side effects and laboratory abnormalities: Sufficient 
information was available to enable comparison of the 
HCV Type
No. 
Patients
OR 
(95% CI)
Heterogeneity Assessment
X2(df) Τ2 I2 P
Genotype 1/4 2715 1.36 
(1.01-1.88) 7.6 (5) 0.04 34% 0.1
Genotype 2  242 4.06
(1.67-9.86) 0.09 (1) 0.00 0 0.7
Genotype 3  102 1.04
(0.47-2.32) 0.2 (3) 0.00 0 0.9
Table 3. OR of achieving SVR in subset of naïve patients who 
received peginterferon alpha-2a against peginterferon alpha-2b.Hepatitis Monthly, Spring 2010; 10(2): 121-131
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Figure 2. Summary estimate of Odds ratios of achieving 
sustained virological response (SVR) with 95% CI in patients 
who were treated with peginterferon alpha-2a plus ribavirin 
versus those treated with peginterferon alpha-2b plus ribavirin.
Figure 3. Summary estimate of Odds ratios of achieving early 
virological response (EVR) with 95% CI in patients who were 
treated with peginterferon alpha-2a plus ribavirin versus those 
treated with peginterferon alpha-2b plus ribavirin.
Figure 4. Summary estimate of Odds ratios of achieving end 
of treatment virological response (ETR) with 95% CI in patients 
who were treated with peginterferon alpha-2a plus ribavirin versus 
those treated with peginterferon alpha-2b plus ribavirin.Hepatitis Monthly, Spring 2010; 10(2): 121-131
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anemia, thrombocytopenia, neutropenia, depression 
or  severe  psychiatric  complications  and  flu-like 
syndrome  rates  between  the  patients  treated  with 
PEG-IFN-α2a plus ribavirin, and those treated with 
PEG-IFN-α2b  plus  ribavirin. The  ORs  were  0.98 
(95% CI 0.84-1.15, I2=0%) for anemia; 1.37 (95% 
CI  0.73-2.58,  I2=0%)  for  thrombocytopenia;  0.88 
(95% CI 0.67-1.15, I2=0%) for depression or severe 
psychiatric complications; and 0.61 (95% CI 0.36-
1.02, I2=85%) for flu-like syndrome in those patients 
who were treated with PEG-IFN-α2a compared with 
those treated with PEG-IFN-α2b.
PEG-IFN-α2a had a higher rate of neutropenia 
[OR=1.50 (95% CI 1.25-1.79, I2=0%)].
Discussion
Pegylation is the process of covalent attachment 
of  polyethylene  glycol  polymer  chains  to  another 
molecule, normally a drug or therapeutic protein. 
PEG-IFN  is  the  most  available  commercial 
product  of  the  pegylation  process.  The  antiviral 
and  immunomodulatory  activity  of  PEG-IFN 
and  the  unmodified  form  of  IFN  are  similar  in 
terms of antiviral activity and receptor binding but 
are  augmented  in  pegylated  form.  The  covalent 
attachment  of  polyethylene  glycol  to  IFN  alpha 
protein, by increasing the molecular weight of IFN, 
has  provided  several  significant  pharmacological 
advantages over the unmodified form of IFN, such 
as:  reduced  dosage  frequency  without  diminished 
efficacy with potentially reduced toxicity, extended 
circulating  life  by  reducing  renal  clearance  and 
enhanced  protection  from  proteolytic  degradation 
and  increased  IFN  molecule  stability  (47,  48). 
The  structure  and  size  of  the  polyethylene  glycol 
moiety and the means of covalent attachment play 
an important role in defining the properties of the 
modified IFN alpha (49). PEG-IFN-α2b is obtained 
by the covalent linking of a linear 12 kDa PEG chain 
to IFN-α2b. In contrast PEG-IFN-α2a has a 40 kDa 
polyethylene glycol moiety, comprising two 20kDa 
chains  (50). These  differences  in  the  polyethylene 
glycol moiety and the position of pegylation results 
in significant differences in the pharmacodynamic 
and pharmacokinetic properties of the two drugs that 
can underlie their differences in viral dynamics and 
antiviral activity. PEG-IFN-α2b is a pro-drug that 
releases IFN alpha-2b, which behaves in the same 
way as standard IFN alpha in terms of its receptor 
binding,  antiviral  activity  and  pharmacokinetic 
properties  (51).  In  contrast,  the  entire  pegylated 
molecule  of  PEG-IFN-α2a  circulates  intact  and 
interacts with the cell surface receptors (52).
PEG-IFN-α2a  is  absorbed  more  slowly  than 
PEG-IFN-α2b; therefore maximum concentrations 
occur later than with PEG-IFN-α2b, but because 
its  molecules  circulate  intact,  and  the  maximum 
concentration sustains up to 168 hours vs. 48-72 
hours  for  PEG-IFN-α2b. Therefore  some  authors 
have  suggested  twice-weekly  administration  of 
PEG-IFN-α2b in some patients (31, 53). Since 2006, 
some RCTs have compared the antiviral activity of 
PEG-IFN-α2a and 2b in clinical settings in terms 
of virological responses at weeks 4, 12, 48 and 72 
after the beginning of therapy, and the safety profile, 
including  the  rate  of  treatment  withdrawals  and 
dose modifications as a result of adverse events or 
hematologic  abnormalities.  By  the  aggregation  of 
these trials, we found a similar pattern of superiority 
of PEG-IFN-α2a over 2b in term of SVR, ETR, 
Figure 5. Summary estimate of Odds ratios of discontinuing the treatment 
with 95% CI in patients who were treated with peginterferon alpha-2a plus 
ribavirin versus those treated with peginterferon alpha-2b plus ribavirin.Hepatitis Monthly, Spring 2010; 10(2): 121-131
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EVR but not RVR. The differences in probabilities 
were 6% (95% CI 1-12%) for SVR, 10% (95% CI 
4-15) for ETR and 7% (95% CI 3-10) for EVR, 
in  favor  of  PEG-IFN-α2a. The  pooled  difference 
for likelihood of RVR was 0.00 (95% CI -5 to 5) 
comprising data from 2865 patients. The likelihood 
of SVR was also greater in PEG-IFN-α2a vs. 2b in 
the subset of naïve patients with both hard-to-treat 
HCV types: genotype 1/4 [6% (95% CI 0-12)] and 
genotype 2 [14% (95% CI 6-22)]. Bruno et al., in 
a  randomized  controlled  trial,  compared  patients’ 
hepatitis C viral dynamics during the first 12 weeks 
of therapy with PEG-IFN-α2a or 2b, and revealed 
the same result as ours. The difference in HCV-RNA 
levels was not significant at week 4 of treatment, but 
was significantly lower at week 12 of treatment in 
patients who received PEG-IFN-α2a (31). It is a very 
important point that the trend was toward PEG-IFN-
α2a, although in the majority of single-study results, 
it did not reach statistical significance. It is important 
to  note  that  those  two  studies  that  showed  the 
significant advantage of PEG-IFN-α2a over 2b were 
published less than 2 months ago, so every narrative 
review or meta-analysis that has been done thus far, 
has concluded that there is a similarity in antiviral 
activity in both PEG-IFNs (19, 54). Our aggregation 
of the data for a safety profile of PEG-IFN-α2a and 
2b showed that discrepancies in dose modification 
and treatment withdrawal in both types of PEG-IFN 
were not significant in total, but neutropenia < 750 c/
mm3 was 1.5 times higher in PEG-IFN-α2a, with no 
observed heterogeneity among studies. This finding 
is confirmed in a study by Antonini et al. (55). Lower 
clearance of PEG-IFN-α2a and longer duration of 
its maximum serum concentration could justify this 
finding (31).
Our meta-analysis has some significant advantages. 
Firstly, all of the included studies had a randomized 
design,  and  as  presented  in  Table  2,  patients  in 
both  treatment  arms  in  all  studies  were  remarkably 
homogeneous, so the results of any single study could 
not simply be attributed to selection bias and differences 
in patients’ baseline characteristics. Secondly, in addition 
to  within-study  homogeneity,  there  was  significant 
homogeneity  regarding  laboratory  abnormalities, 
common  side  effects  and  dose  modifications.  The 
observed  heterogeneity  for  comparative  treatment 
discontinuation and flu-like syndrome could be due to 
different patients’ ethnicity as well as to discordant host 
and environmental factors. 
The modest methodological quality of the included 
studies  is  the  only  limitation  of  the  current  meta-
analysis. Only the study by McHuchison was double 
blind and allocation concealment was unclear in studies 
by  Yenice  and  Sporea  et  al.  and  random  sequence 
generation was not declared in three studies (Table 
1). Methodological research has shown that without 
adequate allocation concealment and blindness, even 
properly developed random allocation sequences can 
be subverted (56). Significant inter-study homogeneities 
and the nature of the final outcome (surrogate) make 
it less possible that the pooled comparative estimate 
of any virological responses was influenced by lack of 
blindness of patients and investigators. Furthermore, 
the trials which adequately reported methodological 
quality  items  are  large,  and  dominate  the  pooled 
estimates of effect. Therefore, it is unlikely that pooled 
estimates are biased. Another limitation of this work 
was lack of, or insufficiency of, data available in the 
literature regarding genotypes other than genotype 1/4 
and relapsers or non-responders to IFN monotherapy 
or to therapy in combination with ribavirin.
Conclusions
PEG-IFN-α2a,  with  similar  safety,  is  more 
effective  than  PEG-IFN-α2b.  A  longer  duration 
of maximum serum concentration compared with 
PEG-IFN-α2b (168 vs. 48-72 h.) yields greater SVR 
and higher neutropenia in PEG-IFN-α2a recipients. 
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